Evidence map›Paper›PMID 42078288›Full record

ArticleCureus2026

Performance Evaluation of the GeneNAT HHH Real-Time Polymerase Chain Reaction System for Simultaneous Detection of Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus.

Bhawna Narula, Malika Grover, Reshu Agarwal, Ekta Gupta

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bhawna NarulaDepartment of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, IND.
Malika GroverDepartment of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, IND.
Reshu AgarwalDepartment of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, IND.
Ekta GuptaDepartment of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) are major blood-borne pathogens responsible for significant global morbidity and mortality. Accurate and early diagnosis is essential for initiating timely treatment and reducing disease transmission. The World Health Organization has highlighted the need for diagnostic tools that are affordable, sensitive, specific, user-friendly, rapid, and robust, particularly in resource-limited settings. This study evaluates the clinical performance of a combined polymerase chain reaction (PCR)-based detection and viral load quantification assay for HBV DNA, HCV RNA, and HIV RNA (HHH assay) using the GeneNAT 300/340 Real-Time PCR System (Genetix Biotech Asia Pvt. Ltd., India) as the test assay. Its performance was compared with established reference assays: the COBAS® AmpliPrep/COBAS® TaqMan® v2.0 (Roche Diagnostics, USA) for HBV and HCV quantification as comparator assay 1 and the Xpert® HIV Viral Load assay (Cepheid, USA) for HIV RNA quantification as comparator assay 2. Methodology A retrospective analysis was conducted using 110 anonymized, de-identified archived plasma samples collected at a tertiary liver care center in India. The cohort comprised a study group of 53 confirmed viral load-positive samples (20 HBV, 18 HCV, and 15 HIV) and a control group of 57 samples negative for HBV, HCV, and HIV infection. For evaluation of diagnostic performance, all archived specimens were tested in parallel using the GeneNAT 300/340 Real-Time PCR System as test assay and the established reference assays: COBAS® AmpliPrep/COBAS® TaqMan® v2.0 for HBV and HCV viral load quantification as comparator assay 1, and the Xpert® HIV Viral Load assay for HIV RNA quantification as comparator assay 2. Results The GeneNAT 300/340 Real-Time PCR assay demonstrated 100% concordance with the comparator assays 1 and 2, with no false-positive or false-negative results observed. The assay achieved 100% sensitivity and specificity for all three infections and delivered results within approximately 60 minutes. Conclusions The GeneNAT 300/340 Real-Time PCR assay shows significant potential to strengthen diagnostic capacity in low- and middle-income countries. Its ease of use, rapid turnaround time, and robust performance make it a strong candidate for broader implementation, including screening in blood banks and peripheral healthcare settings as part of a decentralized diagnostic approach. However, larger-scale prospective studies are required to further establish its clinical utility, cost-effectiveness, and feasibility for widespread adoption.

Indexed as

hepatitis bhepatitis chivreal-time pcrviral hepatitis

Identifiers

PMID42078288
PMCPMC13135233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.